Compare IONQ Inc (IONQ) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? IONQ Inc trades at $31.06 (market cap $14.07B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: IONQ Inc is far larger — about 14.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 34 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| IONQ | MRVI | |
|---|---|---|
Market Cap | $14.07B | $972.90M |
Volume | 23,412,195 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $72.41 | $9.00 |
52-Week Low | $26.59 | $2.83 |
Typical Hold Time | 34 Days | 0 Days |
Enterprise Value | $12.01B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $34.73, down 4.25% today, with a bearish technical signal despite recent earnings beats. The quantum computing company shows explosive revenue growth (2025: $130M, 2026: $246M) but faces significant profitability challenges with a -553% net income margin. Analyst consensus is split with a $65.20 price target suggesting 88% upside potential, while technical indicators show oversold conditions with RSI at 26.86.
The stock presents high-risk, high-reward potential with Wall Street divided on its path to profitability. Key catalysts include quantum technology adoption and manufacturing scaling, while risks center on cash burn and competitive threats in the emerging quantum computing space.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
